
Table S1. Baseline characteristics by prophylactic regimen.

Parameter	None % (Total Number) Or Median/Mean (sd)	LM % (Total Number) Or Median/Mean (Sd)	LR % (Total Number) Or Median/Mean (SD)	*p*-value
n° of patients	83	85	59	-
sex				
male	67.5 (56)	61.2 (52)	50.8 (30)	0.798
female	32.5 (27)	38.8 (33)	49.2 (29)	
age (median, range, in y)	58 (19-80)	57 (35-76)	59 (25-70)	0.911
PTFE-covered stent				
yes	80.7 (67)	65.9 (56)	88.1 (52)	0.944
no	19.3 (15)	34.1 (29)	11.9 (7)	
HE prior TIPS				
yes	9.6 (8)	11.8 (75)	50.8 (30)	-
no	90.4 (75)	88.2 (10)	49.2 (29)	
HE prophylaxis				
none	100 (83)	-	-	**0.002**
RM	-	-	-	0.298
LM	-	100 (85)	-	**0.008**
LR	-	-	100 (59)	**<0.001**
LR+LOLA	-	-	64.4 (38)	**<0.001**
LRonly	-	-	35.6 (21)	**0.046**
etiology of liver disease				
alcoholic	34.9 (29)	61.2 (52)	62.7 (37)	0.594
viral	12.0 (10)	10.6 (9)	1.7 (1)	
NAFLD	9.6 (8)	7.1 (6)	10.2 (6)	
Other	43.4 (36)	21.2 (18)	25.4 (15)	
Child-Pugh grade				
A	42.2 (35)	25.9 (22)	8.5 (5)	**<0.001**
B	54.2 (45)	70.6 (60)	57.6 (34)	
C	3.6 (3)	3.5 (3)	32.2 (19)	
indication for TIPS				
ascites	34.9 (29)	60.0 (51)	50.8 (30)	0.894
variceal bleeding	51.8 (43)	21.2 (18)	25.4 (15)	
both	13.3 811)	18.8 (16)	23.7 (14)	
LTX prior TIPS				
yes	9.6 (8)	3.5 (3)	-	0.319
no	75 (90.4)	96.5 (82)	100 (59)	
HE after TIPS				
yes	51.8 (43)	49.4 (42)	27.1 (16)	0.337
no	48.2 (40)	50.6 (43)	72.9 (43)	
diabetes				
yes	31.3 (26)	27.1 (23)	27.1 (16)	0.940
no	68.7 (57)	72.9 (62)	72.9 (43)	
MELD-score	13.2 (6.8)	13.3 (6.8)	19.2 (6.3)	**<0.001**
bilirubin (mg/dl)	1.15 (1.27)	1.10 (0.78)	2.10 (3.96)	**<0.001**
albumin (g/dl)	3.56 (0.76)	3.19 (0.56)	3.11 (0.51)	0.287

creatinine (mg/dl)	1.26 (0.79)	1.17 (0.62)	1.65 (1.19)	**0.009**
INR	1.21 (0.32)	1.30 (0.26)	1.53(0.41)	0.053
platelets (ths/µl)	133 (70)	144 (144)	128 (73)	0.892
hemoglobin (mg/dl)	10.7 (2.3)	10.6 (1.9)	8.6 (2.0)	**0.002**
PSG (mmHg)	16.7 (6.6)	17.9 (5.2)	17.5 (5.6)	**0.044**

Abbreviations: HE, hepatic encephalopathy; TIPS, transjugular intrahepatic portosystemic shunt; PTFE, polytetrafluoroethylene; NM, no prophylactic medication; LM, lactulose monoprophylaxis; RM, rifaximin monoprophylaxis; LR, lactulose and rifaximin; LOLA, l-ornithin-l-aspartate; LRonly, LR without LOLA; LR+LOLA, LR with LOLA; NAFLD, non-alcoholic fatty liver disease; LTX, liver transplantation; MELD, model of endstage liver disease; INR, international normalized ratio; PSG, portosystemic pressure gradient.



(**a**) (**b**)

Supplementary Figure S1: HE occurrence in patients with *LRonly, LR+LOLA* and *LM/NM*. (**a**) HE occurred 25% of patients with lactulose and rifaximin as HE prophylaxis and in 52.1% of patients with lactulose monoprophylaxis or no prophylactic medication (log-rank test, p<0.05). (**b**) HE occurred 29.7% of patients with lactulose, rifaximin and LOLA as HE prophylaxis and in 52.1% of patients with lactulose monoprophylaxis or no prophylactic medication (log-rank test, p<0.05). LR: lactulose and rifaximin; LM: lactulose monoprophylaxis; none: no prophylactic medication; LR+LOLA: lactulose, rifaximin and LOLA.